DexCom (DXCM)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of DexCom (DXCM)
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Key Insights
Critical company metrics and information
Share Price
$78.41Market Cap
$30.63 BillionTotal Outstanding Shares
390.60 Million SharesTotal Employees
9,600Dividend
No dividendIPO Date
April 14, 2005SIC Description
Surgical & Medical Instruments & ApparatusHomepage
https://www.dexcom.com
Historical Stock Splits
If you bought 1 share of DXCM before June 13, 2022, you'd have 4 shares today.
Execution Date | Split Amount |
---|---|
June 13, 2022 | 4-for-1 |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Operating Activities | $821.70 Million |
Net Cash Flow From Financing Activities, Continuing | $-1.37 Billion |
Net Cash Flow | $-22.40 Million |
Net Cash Flow From Operating Activities, Continuing | $821.70 Million |
Exchange Gains/Losses | $9.90 Million |
Net Cash Flow From Financing Activities | $-1.37 Billion |
Net Cash Flow, Continuing | $-32.30 Million |
Net Cash Flow From Investing Activities, Continuing | $511.10 Million |
Net Cash Flow From Investing Activities | $511.10 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Income/Loss | $680.80 Million |
Cost Of Revenue | $1.51 Billion |
Operating Expenses | $1.81 Billion |
Selling, General, and Administrative Expenses | $1.26 Billion |
Income Tax Expense/Benefit | $63.10 Million |
Basic Average Shares | $788.30 Million |
Gross Profit | $2.44 Billion |
Income Tax Expense/Benefit, Deferred | $13.40 Million |
Operating Income/Loss | $628.00 Million |
Revenues | $3.95 Billion |
Basic Earnings Per Share | $1.73 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Income/Loss From Continuing Operations Before Tax | $743.90 Million |
Net Income/Loss Available To Common Stockholders, Basic | $680.80 Million |
Net Income/Loss Attributable To Parent | $680.80 Million |
Diluted Earnings Per Share | $1.66 |
Costs And Expenses | $3.21 Billion |
Research and Development | $549.00 Million |
Income/Loss From Continuing Operations After Tax | $680.80 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Benefits Costs and Expenses | $3.21 Billion |
Diluted Average Shares | $824.30 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Current Assets | $4.26 Billion |
Noncurrent Assets | $2.09 Billion |
Other Current Assets | $3.61 Billion |
Other Current Liabilities | $1.63 Billion |
Liabilities And Equity | $6.35 Billion |
Current Liabilities | $1.73 Billion |
Equity | $1.98 Billion |
Noncurrent Liabilities | $2.64 Billion |
Equity Attributable To Noncontrolling Interest | $0.00 |
Equity Attributable To Parent | $1.98 Billion |
Prepaid Expenses | $62.50 Million |
Other Non-current Assets | $1.98 Billion |
Wages | $105.80 Million |
Liabilities | $4.37 Billion |
Inventory | $586.30 Million |
Assets | $6.35 Billion |
Intangible Assets | $106.20 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Related Companies
View additional S&P 500 companies similar to DexCom (DXCM)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.